- Nebraska Oncology Society
- The Nebraska Chapter of the American College of Cardiology
- Nebraska Rheumatology Society
- Medication-Assisted Treatment
- Nebraska Dermatology Society
- Nebraska Neurological Society
- Nebraska Radiological Society
- Nebraska Association of Pathologists
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
2020 ASCO Updates on GI Cancers: Is Chemo w/ mFOLFIRINOX More Effective vs. Gemcitabine/nab-Paclitaxel in Resectable PDAC? Should We Use 1L Donafenib vs. Sorafenib in Advanced HCC?
By
Nebraska Oncology Society
FEATURING
George Kim
By
Nebraska Oncology Society
FEATURING
George Kim
14 views
November 30, 2020
Comments 0
Login to view comments.
Click here to Login
Nebraska Oncology Society